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Abstract
Background: Acquired hemophilia A is a rare autoimmune disease with clinically often significant bleeding
diathesis resulting from circulating autoantibodies inhibiting coagulation factor VIII. Half of acquired hemophilia A
cases are associated with an underlying disorder, such as autoimmune diseases, cancer, or use of certain drugs, or
occur during pregnancy and in the postpartum period. In the other half, no underlying cause is identified. An
association of acquired hemophilia A with plasma cell neoplasm seems to be extremely rare.
Case presentation: We describe a case of a 77-year-old Swiss Caucasian man who was diagnosed with acquired
hemophilia A and smoldering multiple myeloma as an underlying cause. Acquired hemophilia A was treated with
prednisolone, cyclophosphamide, and immunoadsorption. Extensive workup revealed a plasma cell neoplasm as
the only disorder associated with or underlying the acquired hemophilia A. For long-term control of acquired
hemophilia A, we considered treatment of the plasma cell neoplasm necessary, and a VRD (bortezomib, lenalidomide,
and dexamethasone) regimen was initiated. Due to multiple complications, VRD was reduced to VRD-lite after two
cycles. After nine cycles of induction therapy and five cycles of consolidation therapy, the patient is in complete
remission of his acquired hemophilia A and very good partial remission of the plasma cell neoplasm. We conducted a
literature review to identify additional cases of this rare association and identified 15 other cases. Case descriptions,
including the sequence of occurrence of acquired hemophilia A and plasma cell neoplasm , treatment, evolution, and
outcome are presented.
Discussion and conclusions: Our case, together with 15 other cases described in the literature, underscore the
possibility of plasma cell neoplasm as an underlying cause of acquired hemophilia A. Physicians should consider
including protein electrophoresis, immunofixation, and analysis of free light chains in laboratory diagnostics when
treating a patient with acquired hemophilia A. The occurrence of excessive and unexplained bleeding in patients
diagnosed with plasma cell neoplasm should raise suspicion of secondary acquired hemophilia A and trigger the
request for coagulation tests, particularly in patients treated with immunomodulatory drugs such as thalidomide or
lenalidomide. Additionally, early intervention with immunoadsorption can be lifesaving in cases with high-titer factor
VIII inhibitors, especially when surgical interventions are necessary.
Keywords: Acquired hemophilia A, Multiple myeloma, Soldering multiple myeloma, Plasma cell diseases, Bleeding
diathesis
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Background
Acquired hemophilia A (AHA) is a rare autoimmune
disease with a clinically significant bleeding diathesis,
resulting from circulating autoantibodies inhibiting co-
agulation factor VIII (FVIII). The incidence is estimated
to be 1–1.5 cases per 1 million population, and AHA is
most often encountered in elderly patients. Half of AHA
cases are associated with an underlying disorder, such as
autoimmune diseases, cancer, use of certain drugs, or
occur during pregnancy, and in the postpartum period.
In the other half, no underlying cause is identified (idio-
pathic AHA). Typically, bleeding is located in the skin,
mucosa, or soft tissues, and, in contrast to congenital
hemophilia, joint bleeding is rare. Mortality in AHA is
increased, particularly in elderly patients and in patients
with underlying malignancies. Despite frequent bleeding
complications and complications of immunosuppressive
therapy, the primary cause of death in AHA is the
underlying disease [1].
Management of AHA is based on four pillars: (1)
avoidance of procedures that may induce bleeding, (2)
control of bleeding, (3) inhibitor eradication, and (4)
treatment of the underlying disease. The mainstays of
bleeding management are bypassing agents, such as
activated prothrombin complex concentrates (aPCCs)
and recombinant activated factor VII (rFVIIa). More
recently, recombinant porcine FVIII, which lacks
complete sequence homology with human FVIII, has
become available. Different strategies, such as im-
munosuppression with steroids alone or in combin-
ation with cyclophosphamide, immunoglobulins,
rituximab, plasma exchange, and immunoadsorption,
are in use for inhibitor elimination and eradication
and, with that, restoration of FVIII clotting activity
[1].
Hematological malignancies may be associated with or
may be the underlying cause of AHA. Among these ma-
lignancies, lymphoproliferative disorders are most com-
mon. An association of AHA with plasma cell neoplasm
(PCN) seems to be extremely rare and to represent only
14% of AHA cases associated with a hematological
malignancy [2]. We describe a case of a 77-year-old man
who presented with AHA and smoldering multiple
myeloma as an underlying cause.
Case presentation
A 77-year-old Swiss Caucasian man was admitted to a
peripheral hospital due to a compartment syndrome of
his left calf following a minor trauma (Fig. 1a). A large
(13 × 8 × 0.6 cm) isolated calf hematoma was docu-
mented on ultrasound, but the patient’s further physical
evaluation was unremarkable. At admission, anticoagu-
lant therapy with apixaban, prescribed for atrial fibrilla-
tion, was interrupted. The patient’s family and personal
history were negative for hematological diseases. Two
months earlier, the patient had undergone an uneventful
colonoscopy with polypectomy initiated because of
melena. No coagulation tests were available from that
time. Despite two surgical interventions, the bleeding
into the calf persisted. Six days after initial admission,
AHA was suspected, and the patient was transferred to
our hospital.
The results of the patient’s laboratory evaluation re-
vealed a prolonged activated partial thromboplastin time
(aPTT; 119 s; reference range 25.0–36.0 s), and FVIII:C
of 2% in the presence of a high-titer FVIII inhibitor of
102 Bethesda units (BU)/ml confirmed the diagnosis of
AHA. Additional diagnostic workup revealed an IgG
kappa paraprotein of 9.2 g/L as well as a slightly reduced
hemoglobin of 106 g/L. The patient’s albumin corrected
serum calcium was 2.38 mmol/L, serum creatinine
103 μmol/L, β2-microglobulin 3.0 mg/L, lactate dehydro-
genase 301 U/L, free light chains kappa 41.1 mg/L and
lambda 10.9 mg/L, and free light chain ratio of 3.77.
Magnetic resonance imaging excluded multiple myeloma
defining focal bone lesions. A subsequent bone marrow
biopsy showed infiltration of clonal plasma cells of 15%
(Fig. 1b). Conventional cytogenetic analysis was not
performed; however, microarray-based comparative gen-
omic hybridization revealed hyperdiploidy with trisomy
3, 4, 5, 9, 11, and 21, whereas the result of fluorescence
in situ hybridization was negative for MYC, IGH
Fig. 1 Findings in our patient. a Presentation of compartment syndrome following surgery. b Plasma cells on bone marrow aspirate
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rearrangement, and 17p. Apart from a smoldering mye-
loma, no other diseases potentially underlying the AHA
were identified.
Treatment with prednisolone (1 mg/kg body weight)
and cyclophosphamide (150 mg/day) was started the day
of presentation at our hospital. Because of imminent
compartment syndrome and potential need of further
surgical interventions, immunoadsorption was started
according to the modified Bonn Malmö protocol [3] to
rapidly deplete the FVIII inhibitor. Altogether, we per-
formed seven immunoadsorption sessions processing ap-
proximately two total patient plasma volumes per
session over the next 13 days. Within 1 month, aPTT
and FVIII:C had normalized, whereas the inhibitor titer
had significantly decreased but was still detectable (1.04
BU/ml).
Insertion of a central venous catheter for immunoad-
sorption, as well as the bone marrow biopsy, were done
under substitution with rFVIIa (NovoSeven; Novo Nor-
disk, Plainsboro, NJ, USA). One to three doses of 90 μg/
kg body weight were applied. Wound healing at the calf
was delayed, and due to skin necrosis, surgical revision
became necessary. At that time, the patient’s aPTT had
already normalized, and substitution with rFVIIa was
not needed.
Lack of complete remission of AHA prompted us to
initiate a VRD (bortezomib, lenalidomide, dexametha-
sone) regimen to treat the patient’s smoldering mye-
loma. After two cycles, the FVIII inhibitor had further
declined to 0.31 BU/ml. The monoclonal immunoglobu-
lin was still detectable by immune fixation but no longer
quantifiable. Subsequently, treatment intensity was
reduced to a VRD-lite regimen [4] because of
thrombocytopenia, mild polyneuropathy, and signs of
congestive heart failure. During follow-up, no further
bleeding occurred. After nine cycles of induction therapy
and five cycles of consolidation therapy with the VRD-
lite regimen, the patient is in complete remission of his
AHA and in very good partial remission of his PCN
(Table 1, patient 16).
Discussion and conclusions
To further elucidate this rare association of AHA and
PCN, we reviewed the published literature in PubMed
using the following search terms: “hemophilia,” “inhibi-
tor,” “factor VIII,” “myeloma,” “plasma cell disorder” or
“neoplasm,” “smoldering myeloma,” “MGUS,” “monoclo-
nal gammopathy,” and “paraprotein.” Our search identi-
fied 15 further cases. Case descriptions, including the
sequence of occurrence of AHA and PCN, treatment,
evolution, and outcome, are provided in Table 1.
We found nine male and seven female patients diag-
nosed with AHA and PCN. Their median age at diagno-
sis of AHA was 61.5 (range 43–87) years. Soft tissue
bleeding was the most common type of bleeding (7 of 16
patients; 43%), in line with other reports [1]. The pa-
tients’ median FVIII inhibitor titer was 18.7 BU/ml
(range 1–102 BU/ml; no data available for two patients).
AHA was diagnosed after excessive postintervention
hemorrhage in two patients and in one patient following
life-threatening pericardial bleeding and hemarthrosis.
AHA with active bleeding was the presenting sign and
preceded PCN diagnosis in six cases (38%) (Table 1,
cases 4, 5, 6, 10, 13, and 16), whereas in the other cases,
PCN was diagnosed first. In three of the latter cases,
AHA was considered to have occurred secondary to
multiple myeloma treatment. The implicated drugs were
interferon alpha, lenalidomide, and thalidomide. Infor-
mation on the type of paraprotein was available in 11
cases, but no particular immunoglobulin type or clonal
light-chain was discernible.
Hemostatic treatment with bypassing agents was ne-
cessary in 11 cases. Their median FVIII inhibitor titer
was 19.2 (range 1–70) BU/ml, whereas the three patients
who did not need hemostatic treatment had FVIII in-
hibitor titers of 4.85, 10, and 102 BU/ml, respectively.
This underscores the fact that FVIII inhibitor titers in
AHA do not necessarily correlate with the severity of
the bleeding manifestations. Our patient received rFVIIa
only prophylactically before catheter insertion and bone
marrow biopsy. Under immunoadsorption, a rapid in-
crease of FVIII clotting activity reaching safe levels was
observed, and further treatment with bypassing products
was not necessary.
Inhibitor eradication was attempted with steroids
alone (n = 4) or in combination with cyclophosphamide
(n = 5), with cyclophosphamide alone (n = 1), and with
rituximab (n = 3). Plasma exchange and immunoadsorp-
tion to remove FVIII antibodies were performed in two
and one patient (our patient), respectively. Given the
long observation period of 55 years, different therapy
regimens were used to treat the underlying PCN in the
16 cases (details are given in Table 1). At the time of
reporting, 13 patients were alive, whereas two of the
three patients who died, died of bleeding complications.
Information on the outcome of AHA and/or PCN was
available for nine of 13 survivors: six had normal coagu-
lation tests, and FVIII activity was mildly reduced in
two. PCN was in complete or partial remission in seven
and two cases, respectively. One patient (case 7 in
Table 1) had a spontaneous remission of his FVIII
inhibitor without any treatment.
In summary, our patient’s case, together with the 15
other cases described in the literature, underscores the
possibility of PCN as an underlying cause of AHA.
Serum and urine protein electrophoresis is not (every-
where) part of standard workup of AHA, and underre-
porting of this association is possible or even likely.
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Accordingly, physicians should consider including pro-
tein electrophoresis, immunofixation, and analysis of free
light chains in laboratory diagnostics when treating a
patient with AHA. The occurrence of excessive and
unexplained bleeding in patients diagnosed with PCN
should raise the suspicion of secondary AHA and trigger
the request for coagulation tests, particularly in patients
treated with immunomodulatory drugs such as thalido-
mide or lenalidomide. Whether PCN treatment alone
can control AHA in these cases remains an open ques-
tion; 11 of 16 (69%) of the reported cases received
treatment for both diseases.
In our experience, early intervention with immuno-
adsorption can be lifesaving in cases with high FVIII in-
hibitor titers, especially in patients requiring a surgical
intervention. The modified Bonn Malmö protocol [3]
is useful to guide AHA therapy that includes
immunoadsorption.
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